<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C7C0FC1F-2464-4404-9921-CAFD2EB08C64"><gtr:id>C7C0FC1F-2464-4404-9921-CAFD2EB08C64</gtr:id><gtr:firstName>Eddie</gtr:firstName><gtr:otherNames>Chung</gtr:otherNames><gtr:surname>Wang</gtr:surname><gtr:orcidId>0000-0002-2243-4964</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/542D5FDB-5D96-4766-AE9C-EC219B87526D"><gtr:id>542D5FDB-5D96-4766-AE9C-EC219B87526D</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Humphreys</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901119"><gtr:id>DEACA185-BFE2-4726-901B-E8C306011A5E</gtr:id><gtr:title>Investigating the modulation of immunity to persistent viral infection by the death receptor 3/TNF-like 1A pathway</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901119</gtr:grantReference><gtr:abstractText>Death Receptor 3 (DR3) is a recently discovered protein that has been shown to control inflammation, the process by which the body responds to injury or irritation by pain, swelling, redness and heat. Normally, inflammation is short-lived and the body recovers quickly, but in certain diseases, inflammation becomes chronic resulting in much longer-term discomfort and can become life-threatening when it affects an essential organ. Inflammatory diseases affect up to 10% of the population at some point in their lives. Recently, DR3 has been suggested as a potential target for new therapies against multiple inflammatory diseases ranging from rheumatoid arthritis to inflammatory bowel disease. This project is designed to increase our understanding of how DR3 controls other aspects of our immune response, namely those to viruses. This is essential as it may reveal potential side-effects that could be associated with therapies targeted against the DR3/TL1A pathway. In addition, the study is designed to reveal other important functions of DR3, which could then be used to manipulate immune responses to our own advantage. In particular, we hope to explore the potential of boosting immunity through activation of the DR3/TL1A pathway, therefore potentially aiding therapies such as vaccines against viruses and cancer.</gtr:abstractText><gtr:technicalSummary>The primary aim of this project is to characterise the contribution of death receptor 3 (DR3) and its only confirmed ligand TNF-like protein 1A (TL1A) to immunity to persistent viruses. This is vitally important as DR3 is emerging as a major regulator of inflammation and anti-TL1A agents have been suggested as a potential therapeutic in a number of inflammatory diseases. Our preliminary data suggests that immunity to the persistent murine cytomegalovirus (MCMV) is impaired in DR3ko mice, which exhibit severe impairment in splenocyte expansion after MCMV challenge and an increase in MCMV titres in the salivary gland 30 days after infection, a readout that represents the establishment of persistent viral infection. Our data indicates that there are both T and non-T cell aspects of immunity to MCMV that are impaired in DR3ko mice. This proposal is designed to further explore the role of DR3 in persistent viral infection using MCMV as a model, in particular investigating whether there is an essential requirement for DR3 in immunity at early and late stages of infection, and to test whether TL1A may be used as an immunotherapeutic tool designed to boost anti-viral T cell responses. The current application has 3 main aims:
I. Characterization of DR3-dependent responses at early stages of MCMV infection
II. Analysis of DR3-dependent T cell responses in persistent MCMV infection
III. Testing of TL1A as a potential therapeutic boost for anti-viral T cell responses</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>373667</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Neurology C</gtr:description><gtr:id>F05D8006-0267-4003-8ECA-A862257705C0</gtr:id><gtr:impact>Publication PMID: 20220013</gtr:impact><gtr:outcomeId>AMq1yTc6Dak-1</gtr:outcomeId><gtr:piContribution>Experiments, expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Neurology A</gtr:description><gtr:id>97FE6014-F5E6-4401-8E7D-88BA76B55028</gtr:id><gtr:impact>Publication PMID: 20220013</gtr:impact><gtr:outcomeId>D4gCYaoHCsa-1</gtr:outcomeId><gtr:partnerContribution>Expertise</gtr:partnerContribution><gtr:piContribution>Experiments, expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Barcelona (UB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Neurology B</gtr:description><gtr:id>AFECEF65-D08E-4709-B3D3-8E500872619D</gtr:id><gtr:impact>Publication PMID: 20220013</gtr:impact><gtr:outcomeId>pXqtXg3zBU3-1</gtr:outcomeId><gtr:piContribution>Experiments, expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Biochemistry and Immunology</gtr:department><gtr:description>MCMV</gtr:description><gtr:id>9A36BD01-F7F7-4633-91A2-B1B993AF3164</gtr:id><gtr:impact>Successful grant funding - MRC Project Grant awarded in 2009</gtr:impact><gtr:outcomeId>ECEA03E9405-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input and reagents</gtr:partnerContribution><gtr:piContribution>Staff, reagents, intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biosciences</gtr:department><gtr:description>Atherosclerosis</gtr:description><gtr:id>95220E57-0A5B-41FE-A702-14510924DF24</gtr:id><gtr:impact>Publication PMID: 20410491</gtr:impact><gtr:outcomeId>npq77UxqLCd-1</gtr:outcomeId><gtr:partnerContribution>Expertise and experiments</gtr:partnerContribution><gtr:piContribution>Expertise and experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection and Immunity</gtr:department><gtr:description>Inflammation</gtr:description><gtr:id>3A5799FA-815B-48B9-B567-E14914658DBE</gtr:id><gtr:impact>Publication PMID: 20826539, PhD studentship funding</gtr:impact><gtr:outcomeId>rVNXSipYypC-1</gtr:outcomeId><gtr:partnerContribution>Expertise, reagents, experiments</gtr:partnerContribution><gtr:piContribution>Expertise, ideas, some research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3A75EEBA-D7C0-4937-8FD4-FD4A3A7BCBF7</gtr:id><gtr:outcomeId>56c60be5eec4d9.00349410</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35821</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>ISSF Seedcorn Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>AC1120IF05</gtr:fundingRef><gtr:id>1FB57666-5D58-4C08-8DC8-FB686C2F6CAA</gtr:id><gtr:outcomeId>56c60d99cf5191.16972936</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC GSK CASE Studentship (top-up)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>7A5E788D-28A3-4F1D-9678-E6C370396C8B</gtr:id><gtr:outcomeId>Km2MddFqtSj</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8252</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Commercial Supply</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>5BB0C3F5-89D1-4DFD-9A4A-D765961D0F11</gtr:id><gtr:outcomeId>56c60cec4988a0.13053840</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4739</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Commercial Supply</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>91AC4CBB-529C-4A0E-AB3B-CCEA26EB40BA</gtr:id><gtr:outcomeId>56c60c9c9d7021.43832639</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16209</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Award</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CD3EDDB7-317B-4AF6-96E1-1EF2A8787773</gtr:id><gtr:outcomeId>JXLqENtMmxZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65558</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Equipment Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>C777C784-5BE9-41EA-845E-C6C85B57E745</gtr:id><gtr:outcomeId>ViJx2Vkkisd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>DR3ko mice generated by backcrosses onto a DBA/1 background</gtr:description><gtr:id>B32DFDFD-68DE-421E-97F8-21DB96A1AAEC</gtr:id><gtr:impact>DR3ko DBA/1 mice are lethally susceptible to MCMV infection at low doses. They have also been used to investigate models of collagen-induced arthritis and ankylosing spondylitis.</gtr:impact><gtr:outcomeId>DQwSAT4GRDg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DR3ko DBA/1 background</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E49FEC21-0F7F-45CC-BF78-2AE7D28C8784</gtr:id><gtr:title>An essential role for death receptor 3 in experimental autoimmune uveoretinitis.</gtr:title><gtr:parentPublicationTitle>Ocular immunology and inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c24c1d0733cad33b16bfea6481e351"><gtr:id>11c24c1d0733cad33b16bfea6481e351</gtr:id><gtr:otherNames>Calder CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0927-3948</gtr:issn><gtr:outcomeId>pm_13467_27_22486262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01E1E61C-AC54-4168-A413-45298C85D666</gtr:id><gtr:title>Quantitative temporal viromics: an approach to investigate host-pathogen interaction.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b895d6f1022449850bff9b154540eb7"><gtr:id>6b895d6f1022449850bff9b154540eb7</gtr:id><gtr:otherNames>Weekes MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>545b483b1df794.45666941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2493D97E-5B38-4BA5-A419-B1AB07692C46</gtr:id><gtr:title>Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice.</gtr:title><gtr:parentPublicationTitle>Journal of immunology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4a0e5080b3c5c0d127bae4a48596ef5"><gtr:id>b4a0e5080b3c5c0d127bae4a48596ef5</gtr:id><gtr:otherNames>Collins FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2314-7156</gtr:issn><gtr:outcomeId>5675e64b26a37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C3D9B7C-60B5-431F-A081-45A27DB22B76</gtr:id><gtr:title>Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf565f746b8db763e1aa7c73394b8ee2"><gtr:id>cf565f746b8db763e1aa7c73394b8ee2</gtr:id><gtr:otherNames>Twohig JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>e5pkj79xqKs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D611BBBA-95C3-422F-9887-59C68D10ECF2</gtr:id><gtr:title>Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f265ab61f417b0ab947659a50ee41c38"><gtr:id>f265ab61f417b0ab947659a50ee41c38</gtr:id><gtr:otherNames>Taraban VY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>LoQBCwSML6W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41411A83-32EE-4B1A-9A14-718CE93DA83D</gtr:id><gtr:title>The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4? and CD8? T-cell immunity.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf565f746b8db763e1aa7c73394b8ee2"><gtr:id>cf565f746b8db763e1aa7c73394b8ee2</gtr:id><gtr:otherNames>Twohig JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_13467_27_22593543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>980C931B-5A8A-4E4C-AAC0-8DE8D673B943</gtr:id><gtr:title>Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4f1e8c0a6c1979027a09dcd792a65e"><gtr:id>cb4f1e8c0a6c1979027a09dcd792a65e</gtr:id><gtr:otherNames>Jones GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>doi_55f9839836e1028d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAD352A6-A7D1-4518-96A8-B1E8C9B440B2</gtr:id><gtr:title>Rapid early innate control of hepatitis C virus during IFN-a treatment compromises adaptive CD4+ T-cell immunity.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/338562ea0b5659f52819859605ebb987"><gtr:id>338562ea0b5659f52819859605ebb987</gtr:id><gtr:otherNames>Pembroke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13467_27_22653709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>694F3E38-1358-42F5-8D2A-7DB2EC508D47</gtr:id><gtr:title>Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb777def93736c47035c026bce6bd26c"><gtr:id>eb777def93736c47035c026bce6bd26c</gtr:id><gtr:otherNames>Wang EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>545b483b438695.81803589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9785D77-D42B-4AF5-BE19-AD838DAD27A8</gtr:id><gtr:title>A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ce8d0a6661a0c835b9b18e764a7bfe"><gtr:id>04ce8d0a6661a0c835b9b18e764a7bfe</gtr:id><gtr:otherNames>Jia LG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58ac50ff4a3806.04982434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15FA03EF-46BC-427B-B25A-507BA48B9C63</gtr:id><gtr:title>IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/766b9ac2fc7a6a74db1e0376e5a80d08"><gtr:id>766b9ac2fc7a6a74db1e0376e5a80d08</gtr:id><gtr:otherNames>Stacey MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13467_27_21849677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65FFDC3D-E623-4925-AE62-DA2614DBE066</gtr:id><gtr:title>Death Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation.</gtr:title><gtr:parentPublicationTitle>Cellular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a62d18124c7ed4073f2b64f579d5f"><gtr:id>567a62d18124c7ed4073f2b64f579d5f</gtr:id><gtr:otherNames>Singh RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-8749</gtr:issn><gtr:outcomeId>5aa28b094eec42.62843057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>523916DE-0A57-4D88-AE09-F7BB3620BA94</gtr:id><gtr:title>CD4+ T cells, human cytomegalovirus and end-stage renal disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb777def93736c47035c026bce6bd26c"><gtr:id>eb777def93736c47035c026bce6bd26c</gtr:id><gtr:otherNames>Wang EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>pm_13467_27_21460358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D762F0AE-DEDB-41DD-8F2E-BB368680CEA1</gtr:id><gtr:title>The role of tumor necrosis factor receptor superfamily members in mammalian brain development, function and homeostasis.</gtr:title><gtr:parentPublicationTitle>Reviews in the neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf565f746b8db763e1aa7c73394b8ee2"><gtr:id>cf565f746b8db763e1aa7c73394b8ee2</gtr:id><gtr:otherNames>Twohig JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0334-1763</gtr:issn><gtr:outcomeId>pm_13467_27_21861782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3B24BB0-FF25-42CB-8FCD-2D3F2B2D23CF</gtr:id><gtr:title>HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>545b483b6b24d5.92741008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BFC7A46-0A71-4465-AAED-56969C233C52</gtr:id><gtr:title>CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed4e5d070a6f9c6d130c206a31b64979"><gtr:id>ed4e5d070a6f9c6d130c206a31b64979</gtr:id><gtr:otherNames>Coles SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13467_27_21274000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E281F97-D725-4C46-9C98-E6C37044A683</gtr:id><gtr:title>Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58e38151138fdd15af992c15175ac172"><gtr:id>58e38151138fdd15af992c15175ac172</gtr:id><gtr:otherNames>Prod'homme V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13467_27_22345649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEFA5E21-EF69-4FEA-9E99-3584F4D81AEB</gtr:id><gtr:title>Expression of CD200 on AML blasts directly suppresses memory T-cell function.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed4e5d070a6f9c6d130c206a31b64979"><gtr:id>ed4e5d070a6f9c6d130c206a31b64979</gtr:id><gtr:otherNames>Coles SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13467_27_22430635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C645FA92-2908-4F57-80ED-2B5EE811050C</gtr:id><gtr:title>CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4a0e5080b3c5c0d127bae4a48596ef5"><gtr:id>b4a0e5080b3c5c0d127bae4a48596ef5</gtr:id><gtr:otherNames>Collins FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn><gtr:outcomeId>58ac50ff732636.39397281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F71217FE-9354-41A9-B109-98C9F71BA9FD</gtr:id><gtr:title>Human cytomegalovirus: taking the strain.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8a2735a3ab0c4d75ed431e7759769ce"><gtr:id>d8a2735a3ab0c4d75ed431e7759769ce</gtr:id><gtr:otherNames>Wilkinson GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>56c608d8b09a22.62821969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49990660-E9BE-499F-A779-C5C398850847</gtr:id><gtr:title>Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed4e5d070a6f9c6d130c206a31b64979"><gtr:id>ed4e5d070a6f9c6d130c206a31b64979</gtr:id><gtr:otherNames>Coles SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_13467_27_22430636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22675661-2B90-4F00-A745-99B64BA710EB</gtr:id><gtr:title>Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976a10b638e251388f0bb8ff3b066bad"><gtr:id>976a10b638e251388f0bb8ff3b066bad</gtr:id><gtr:otherNames>Perks WV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58ac50fee2efb1.90015252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34EB6514-289A-48EB-A24F-6A7AFFB7B003</gtr:id><gtr:title>DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b998be4188d5c8d563cef6a1110d03e9"><gtr:id>b998be4188d5c8d563cef6a1110d03e9</gtr:id><gtr:otherNames>Al-Lamki RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_13467_27_22330679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A94CE356-6236-4B1F-8EE1-DDB704BF7D82</gtr:id><gtr:title>Review: Novel Insights Into Tumor Necrosis Factor Receptor, Death Receptor 3, and Progranulin Pathways in Arthritis and Bone Remodeling.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66ef18d27aaab3e2eb29829908cf1ed4"><gtr:id>66ef18d27aaab3e2eb29829908cf1ed4</gtr:id><gtr:otherNames>Williams A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>58ac50ff272c47.28846831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47832139-AFA8-44A1-B869-C3566F2660A0</gtr:id><gtr:title>Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4db494963f9a272576ab42849a536cb6"><gtr:id>4db494963f9a272576ab42849a536cb6</gtr:id><gtr:otherNames>Fielding CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>545b483aeb18a2.07014995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8330944-9263-4E94-9085-AAF895FCEC02</gtr:id><gtr:title>RORa-expressing T regulatory cells restrain allergic skin inflammation.</gtr:title><gtr:parentPublicationTitle>Science immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f8be428c0f52633fa9173c473c8db5"><gtr:id>d6f8be428c0f52633fa9173c473c8db5</gtr:id><gtr:otherNames>Malhotra N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2470-9468</gtr:issn><gtr:outcomeId>5aa28b0984dbe3.77141206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E292CEEE-DC3B-4E96-88BE-D3961324DBAF</gtr:id><gtr:title>The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7404c9ae8e2c662f4f25c5bfd1c6a84"><gtr:id>d7404c9ae8e2c662f4f25c5bfd1c6a84</gtr:id><gtr:otherNames>McLaren JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13467_27_20410491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC3A470-9314-4F4A-9519-0AA78F396DEA</gtr:id><gtr:title>Characterization of death receptor 3-dependent aortic changes during inflammatory arthritis.</gtr:title><gtr:parentPublicationTitle>Pharmacology research &amp; perspectives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/275dd0ecd8decd64841406624ee38640"><gtr:id>275dd0ecd8decd64841406624ee38640</gtr:id><gtr:otherNames>Williams JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2052-1707</gtr:issn><gtr:outcomeId>585d32178ed0d6.68348981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB638E35-F9D6-4295-A3D7-5F041FD48085</gtr:id><gtr:title>Herpesvirus exploitation of host immune inhibitory pathways.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97845ef870b3e596f4facb73ca3ff26c"><gtr:id>97845ef870b3e596f4facb73ca3ff26c</gtr:id><gtr:otherNames>Stack G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_13467_27_23012619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDA9EFB0-8BD4-4204-A3C9-58CD0958900E</gtr:id><gtr:title>On death receptor 3 and its ligands.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb777def93736c47035c026bce6bd26c"><gtr:id>eb777def93736c47035c026bce6bd26c</gtr:id><gtr:otherNames>Wang EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_13467_27_22612445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD4EF60-8968-47E4-9FBA-65CBFEE45C9E</gtr:id><gtr:title>The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.</gtr:title><gtr:parentPublicationTitle>Antiviral chemistry &amp; chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d70f79ddb10659f4b9e446ebaf2d628"><gtr:id>4d70f79ddb10659f4b9e446ebaf2d628</gtr:id><gtr:otherNames>Holcakova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0956-3202</gtr:issn><gtr:outcomeId>rC4J1sDvkyT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7F1EBF9-4C2D-4C37-BB2A-D770F0B86853</gtr:id><gtr:title>Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89314afe407ab0f79cf15f9d0f030d85"><gtr:id>89314afe407ab0f79cf15f9d0f030d85</gtr:id><gtr:otherNames>Smith W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>56c6126cea62e1.63016717</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901119</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>